$Recursion Pharmaceuticals (RXRX.US)$ IndustryHealth care, b...

IndustryHealth care, biotechnology.

Business Overview
Using its proprietary platform utilizing artificial intelligence (AI), it is advancing the discovery and development of new pharmaceuticals.
・AI drug discovery platform: Analyze large biological datasets with AI to identify molecules causing diseases and new compounds that interact with them.
・Drug discovery pipeline: Developing new drug candidates for various diseases based on compounds discovered on our platform.
・Platform licensing: We may license our platform to other pharmaceutical companies for collaborative research.

Main customers:
Recursion Pharmaceuticals' main business model is partnering and collaborating with pharmaceutical companies. Therefore,Major pharmaceutical companiesCan be said to be the main customer base.

Outlook for the Future
With the advancement of artificial intelligence (ai), the importance of ai drug discovery is increasing. Recursion Pharmaceuticals, as a pioneer in this field, is expected to continue to experience high growth.
・Pipeline Progress: Multiple new drug candidates are advancing to the clinical trial stage, and the future progress of the pipeline is expected to significantly impact performance.
・Advancement of AI Technology: The further advancement of AI technology enables more efficient pharmaceutical development, enhancing competitiveness.
・Collaboration with pharmaceutical companies: By strengthening partnerships with major pharmaceutical companies and advancing joint research, it is possible to expand the business.

・AI Supercomputer: Recursion Pharmaceuticals utilizes AI in drug discovery, incorporating NVIDIA's GPUs into supercomputers responsible for advanced computational processing. NVIDIA's GPUs are known for their high performance in AI processing, playing a crucial role in accelerating Recursion's drug discovery process.

Investment Relationship: Nvidia holds a large amount of shares in Recursion Pharmaceuticals and is making significant investments. This investment aims to deepen the technical synergy between both companies and strengthen cooperation in the field of AI drug discovery.

Technical Cooperation: Both companies are advancing research and development together, combining Nvidia's state-of-the-art AI technology with Recursion's biological data and drug discovery platform to aim for the development of new treatments.

Utilizing AI in drug discovery holds the potential for discovering new medications more rapidly and efficiently compared to traditional drug discovery methods.
There are numerous untreated diseases, and there is high demand for new treatment methods. AI drug discovery is gaining attention as a promising approach to address this unmet medical need.